Eton Cares is Here to Help You

Sign up to learn more about our full-service patient program designed to help you and your child along the treatment journey.

Sign up now to receive helpful updates and information about Eton Cares:

Patients who have been prescribed Increlex are automatically enrolled in Eton Cares.* Our reliable professionals are fully trained on Increlex and SPIGFD.

Insurance Specialists provide personalized assistance and ongoing support
Dedicated Pharmacists are available 24/7 to provide patient support by phone, worry-free refill reminders, and shipment alerts

Eton Cares provides copay and financial support

Copay Support - Eton Cares can help eligible, commercially insured patients get their medication for as little as $0 per month*
Financial Support - Patients who do not have insurance and meet certain financial requirements may be eligible for additional financial support from a Patient Assistance Program*

*Subject to eligibility criteria. Terms and conditions apply.

There was a problem with your submission. Errors have been highlighted below.

Name

How is your child's condition currently being treated? *

Are you enrolled in Eton Cares? *

Yes

Yes, I want to receive information from Eton Pharmaceuticals. I certify that I am at least 18 years old and I understand that I am sharing my health information, and I have reviewed the . I acknowledge that I can opt out of receiving this information at any time by clicking the unsubscribe link at the bottom of all email correspondence. We are collecting personal information in order to fulfill your request. Please see Eton's Privacy Policy

We are collecting personal information in order to fulfill your request. Please see Eton's privacy policy at https://www.etonpharma.com/us/privacy-cookie.

INDICATION

INCRELEX^® (mecasermin) is indicated for the treatment of growth failure in pediatric patients aged 2 years and older with severe primary IGF-1 deficiency* (IGFD), or with hormone (GH) gene deletion who have developed neutralizing antibodies to GH.

Limitations of use: INCRELEX is not a substitute to GH for approved GH indications. INCRELEX is not indicated for use in patients with secondary forms of IGFD, such as GH deficiency, malnutrition, hypothyroidism, or chronic treatment with pharmacologic doses of anti-inflammatory steroids.

*Severe primary IGF-1 deficiency (IGFD) is defined by height standard deviation score ≤ -3.0 and basal IGF-1 standard deviation score ≤ -3.0 and normal or elevated GH.

IMPORTANT SAFETY INFORMATION

Contraindications

Hypersensitivity: to mecasermin (rhIGF-1), any of the inactive ingredients in INCRELEX, or who have experienced a severe hypersensitivity to INCRELEX. Allergic reactions have been reported, including anaphylaxis requiring hospitalization.

Intravenous Administration

Closed Epiphyses

Malignant Neoplasia in pediatric patients with malignant neoplasia or a history of malignancy.

Warnings and Precautions

Hypoglycemia: INCRELEX should be administered 20 minutes before or after a meal or snack and should not be administered when the meal or snack is omitted. Glucose monitoring and INCRELEX dose titration are recommended until a well-tolerated dose is established and as medically indicated.
Intracranial Hypertension: Funduscopic examination is recommended at the initiation of and periodically during the course of therapy.
Lymphoid Tissue Hypertrophy: Patients should have periodic examinations to rule out potential complications.
Slipped Capital Femoral Epiphysis: Carefully evaluate any pediatric patient with the onset of a limp or hip/knee pain during INCRELEX therapy.
Progression of Scoliosis: Patients with a history of scoliosis, treated with INCRELEX, should be monitored.
Malignant Neoplasia: There have been postmarketing reports of malignant neoplasia in pediatric patients who received treatment with INCRELEX. The tumors were observed more frequently in patients who received INCRELEX at higher than recommended doses or at doses that produced serum IGF-1 levels above the normal reference ranges for age and sex. Monitor all patients receiving INCRELEX carefully for development of neoplasms. If malignant neoplasia develops, discontinue INCRELEX treatment.
Risk of Serious Adverse Reactions in Infants due to Benzyl Alcohol Preserved Solution: Serious and fatal adverse reactions including “gasping syndrome” can occur in neonates and infants treated with benzyl alcohol-preserved drugs. Use of INCRELEX in infants is not recommended.

Adverse Reactions

Common adverse reactions include hypoglycemia, local and systemic hypersensitivity, and tonsillar hypertrophy.

To report a suspected adverse event related to INCRELEX, contact Eton Pharmaceuticals, Inc. at 1-855-224-0233 or the U.S. Food and Drug Administration (FDA) at www.fda.gov/safety/Medwatch or call 1-800-FDA-1088.

Please see full Prescribing Information for more information.